


What is claimed is:

1. A compound having the structure:

5

10



15

wherein X is CR<sub>7</sub>; N; or N<sup>+</sup>O<sup>-</sup>;

wherein Y is O; CO; S; CR<sub>3</sub>R<sub>5</sub>; or NR<sub>6</sub>;

20

wherein each R<sub>2</sub> is independently H; F; Cl; Br; I; -NO<sub>2</sub>, -CN; straight chained or branched C<sub>1</sub>-C<sub>4</sub> alkyl; C<sub>1</sub>-C<sub>4</sub> monofluoroalkyl or C<sub>1</sub>-C<sub>4</sub> polyfluoroalkyl; straight chained or branched C<sub>1</sub>-C<sub>4</sub> alkoxy; -OH; -(CH<sub>2</sub>)<sub>q</sub>OH; -COR<sub>4</sub>; CO<sub>2</sub>R<sub>4</sub>; CONHR<sub>4</sub>; phenyl; or benzyl;

25

wherein each R<sub>3</sub> is independently H; straight chained or branched C<sub>1</sub>-C<sub>4</sub> alkyl; C<sub>1</sub>-C<sub>4</sub> monofluoroalkyl or C<sub>1</sub>-C<sub>4</sub> polyfluoroalkyl; straight chained or branched C<sub>1</sub>-C<sub>4</sub> alkoxy; -(CH<sub>2</sub>)<sub>q</sub>OH; -OH; =N-OR<sub>4</sub>; COR<sub>4</sub>; CO<sub>2</sub>R<sub>4</sub>; CONHR<sub>4</sub>; phenyl; or benzyl;

30

wherein each R<sub>4</sub> is independently H; straight chained or branched C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> monofluoroalkyl or C<sub>1</sub>-C<sub>4</sub> polyfluoroalkyl; or phenyl;

wherein each  $R_5$  is independently H; straight chained or branched  $C_1-C_4$  alkyl,  $C_1-C_4$  monofluoroalkyl, or  $C_1-C_4$  polyfluoroalkyl;

5 wherein  $R_6$  is H; straight chained or branched  $C_1-C_4$  alkyl;  $C_1-C_4$  monofluoroalkyl or  $C_1-C_4$  polyfluoroalkyl; straight chained or branched  $C_1-C_4$  alkoxy; -  
 $CH_2CH_2(CH_2)_qOH$ ;  $COR_4$ ;  $CO_2R_4$ ;  $CONHR_4$ ; phenyl; or benzyl;

10 wherein each  $R_7$  is independently H; -CN; straight chained or branched  $C_1-C_4$  alkyl;  $C_1-C_4$  monofluoroalkyl or  $C_1-C_4$  polyfluoroalkyl; straight chained or branched  $C_1-C_4$  alkoxy; -OH;  $-(CH_2)_qOH$ ;  $-COR_4$ ;  $CO_2R_4$ ;  $CONHR_4$ ; phenyl; or benzyl;

15 wherein m and n are each independently 0, 1, 2 or 3, provided that  $m+n$  is 2 or 3;


wherein each p is independently 0, 1 or 2; and

20 wherein each q is independently 0, 1, 2 or 3;

or a pharmaceutically acceptable salt thereof.

25

2. A compound having the structure:



wherein each of Z1, Z2 and Z3 is N or CR<sub>2</sub>, with the proviso that either one of Z1, Z2 or Z3 is N and the others of Z1, Z2 or Z3 are CR<sub>2</sub>, or both Z1 and Z3 are N and Z2 is CR<sub>2</sub>;

wherein R<sub>1</sub> is H; F; straight chained or branched C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> monofluoroalkyl or C<sub>1</sub>-C<sub>4</sub> polyfluoroalkyl; straight chained or branched C<sub>1</sub>-C<sub>4</sub> alkoxy, -OH; or - (CH<sub>2</sub>)<sub>q</sub>OH;

wherein each R<sub>2</sub> is independently H; F; Cl; Br; I; -NO<sub>2</sub>, -CN; straight chained or branched C<sub>1</sub>-C<sub>4</sub> alkyl; C<sub>1</sub>-C<sub>4</sub> monofluoroalkyl or C<sub>1</sub>-C<sub>4</sub> polyfluoroalkyl; straight chained or branched C<sub>1</sub>-C<sub>4</sub> alkoxy; -OH; - (CH<sub>2</sub>)<sub>q</sub>OH; -COR<sub>4</sub>; CO<sub>2</sub>R<sub>4</sub>; CONHR<sub>4</sub>; phenyl; or benzyl;

wherein each R<sub>4</sub> is independently H; straight chained or branched C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> monofluoroalkyl or C<sub>1</sub>-C<sub>4</sub> polyfluoroalkyl; or phenyl; and

wherein q is each independently 0, 1, 2 or 3;


or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 or 2, wherein the compound comprises the (+) enantiomer.
- 5 4. The compound of claim 1 or 2, wherein the compound comprises the (-) enantiomer.
5. The compound of claim 1, wherein Y is  $\text{CR}_3\text{R}_5$ , and m+n is 3.
- 10 6. The compound of claim 1, wherein Y is  $\text{CR}_3\text{R}_5$  and m+n is 2.
7. The compound of claim 1, wherein Y is  $\text{NR}_6$ .
- 15 8. The compound of claim 1, wherein X is N.
9. The compound of claim 2, wherein two of Z1, Z2 and Z3 are  $\text{CR}_2$  and the other is N.
- 20 10. The compound of claim 5, wherein p is at least 1 and at least one  $\text{R}_3$  is methyl.
11. The compound of claim 5, wherein at least one  $\text{R}_2$  is methyl.
- 25 12. The compound of claim 6, wherein at least one  $\text{R}_2$  is bromo.
13. The compound of any one of claims 10, 11, or 12, wherein X is N.
- 30 14. The compound of claim 9, wherein at least one  $\text{R}_2$  is methyl or phenyl.

15. The compound of claim 9, wherein  $R_1$  is  $C_1-C_3$  alkyl,  $C_1-C_3$  alkoxy, or -OH.


16. The compound of claim 6 having the structure:

5



10

15 17. The compound of claim 6 having the structure:




20

25

30

18. The compound of claim 6 having the structure:


5



10

19. The compound of claim 12 having the structure:


15



20

20. The compound of claim 15 having the structure:

25




30

21. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 or 2 and a pharmaceutically acceptable carrier.

5 22. A method for treating an  $\alpha_2$  adrenergic receptor associated disorder in a subject, which comprises administering to the subject an amount of a compound effective to treat the disorder, wherein the compound has the structure:

10



15

20

wherein X is CR<sub>7</sub>; N; or N<sup>+</sup>O<sup>-</sup>;

wherein Y is O; CO; S; CR<sub>3</sub>R<sub>5</sub>; or NR<sub>6</sub>;

25

wherein each R<sub>2</sub> is independently H; F; Cl; Br; I; -NO<sub>2</sub>, -CN; straight chained or branched C<sub>1</sub>-C<sub>4</sub> alkyl; C<sub>1</sub>-C<sub>4</sub> monofluoroalkyl or C<sub>1</sub>-C<sub>4</sub> polyfluoroalkyl; straight chained or branched C<sub>1</sub>-C<sub>4</sub> alkoxy; -OH; -(CH<sub>2</sub>)<sub>q</sub>OH; -COR<sub>4</sub>; CO<sub>2</sub>R<sub>4</sub>; CONHR<sub>4</sub>; phenyl; or benzyl;

30

wherein each R<sub>3</sub> is independently H; straight chained or branched C<sub>1</sub>-C<sub>4</sub> alkyl; C<sub>1</sub>-C<sub>4</sub> monofluoroalkyl or C<sub>1</sub>-C<sub>4</sub> polyfluoroalkyl; straight chained or branched C<sub>1</sub>-C<sub>4</sub> alkoxy; -(CH<sub>2</sub>)<sub>q</sub>OH; -OH; =N-OR<sub>4</sub>; COR<sub>4</sub>; CO<sub>2</sub>R<sub>4</sub>; CONHR<sub>4</sub>; phenyl; or benzyl;

35

wherein each  $R_4$  is independently H; straight chained or branched  $C_1-C_4$  alkyl;  $C_1-C_4$  monofluoroalkyl or  $C_1-C_4$  polyfluoroalkyl; or phenyl;

5 wherein each  $R_5$  is independently H; straight chained or branched  $C_1-C_4$  alkyl,  $C_1-C_4$  monofluoroalkyl, or  $C_1-C_4$  polyfluoroalkyl;

10 wherein  $R_6$  is H; straight chained or branched  $C_1-C_4$  alkyl;  $C_1-C_4$  monofluoroalkyl or  $C_1-C_4$  polyfluoroalkyl; straight chained or branched  $C_1-C_4$  alkoxy; -  
 $CH_2CH_2(CH_2)_qOH$ ;  $COR_4$ ;  $CO_2R_4$ ;  $CONHR_4$ ; phenyl; or benzyl;

15 wherein each  $R_7$  is independently H; -CN; straight chained or branched  $C_1-C_4$  alkyl;  $C_1-C_4$  monofluoroalkyl or  $C_1-C_4$  polyfluoroalkyl; straight chained or branched  $C_1-C_4$  alkoxy; -OH;  $-(CH_2)_qOH$ ;  $-COR_4$ ;  $CO_2R_4$ ;  $CONHR_4$ ; phenyl; or benzyl;

20 wherein m and n are each independently 0, 1, 2 or 3, provided that m+n is 2 or 3;

wherein each p is independently 0, 1 or 2; and


25 wherein each q is independently 0, 1, 2 or 3;

or a pharmaceutically acceptable salt thereof.

30



23. A method for treating an  $\alpha_1$  adrenergic receptor associated disorder in a subject, which comprises administering to the subject an amount of a compound effective to treat the disorder, wherein the compound has the structure:



wherein each of Z1, Z2 and Z3 is N or CR<sub>2</sub>, with the proviso that either one of Z1, Z2 or Z3 is N and the others of Z1, Z2 or Z3 are CR<sub>2</sub>, or both Z1 and Z3 are N and Z2 is CR<sub>2</sub>;


wherein R<sub>1</sub> is H; F; straight chained or branched C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> monofluoroalkyl or C<sub>1</sub>-C<sub>4</sub> polyfluoroalkyl; straight chained or branched C<sub>1</sub>-C<sub>4</sub> alkoxy, -OH; or -(CH<sub>2</sub>)<sub>q</sub>OH;

wherein each R<sub>2</sub> is independently H; F; Cl; Br; I; -NO<sub>2</sub>, -CN; straight chained or branched C<sub>1</sub>-C<sub>4</sub> alkyl; C<sub>1</sub>-C<sub>4</sub> monofluoroalkyl or C<sub>1</sub>-C<sub>4</sub> polyfluoroalkyl; straight chained or branched C<sub>1</sub>-C<sub>4</sub> alkoxy; -OH; -(CH<sub>2</sub>)<sub>q</sub>OH; -COR<sub>4</sub>; CO<sub>2</sub>R<sub>4</sub>; CONHR<sub>4</sub>; phenyl; or benzyl;

wherein each R<sub>4</sub> is independently H; straight chained or branched C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> monofluoroalkyl or C<sub>1</sub>-C<sub>4</sub> polyfluoroalkyl; or phenyl; and

5        24. The method of claim 22 or 23, wherein the disorder is  
migraine headache, hypertension or glaucoma.

25. A method for treating pain in a subject, which comprises administering to the subject an amount of a compound effective to treat the subject's pain, wherein the compound has the structure:



wherein Y is O; CO; S; CR<sub>3</sub>R<sub>5</sub>; or NR<sub>5</sub>;

wherein each  $R_2$  is independently H; F; Cl; Br; I;  $-NO_2$ ,  
-CN; straight chained or branched  $C_1$ - $C_4$  alkyl;  $C_1$ - $C_4$   
monofluoroalkyl or  $C_1$ - $C_4$  polyfluoroalkyl; straight  
chained or branched  $C_1$ - $C_4$  alkoxy; -OH;  $-(CH_2)_3OH$ ;  $-COR_3$ ;  
30  $CO_2R_4$ ;  $CONHR_3$ ; phenyl; or benzyl;

wherein each R<sub>3</sub> is independently H; straight chained or branched C<sub>1</sub>-C<sub>4</sub> alkyl; C<sub>1</sub>-C<sub>4</sub> monofluoroalkyl or C<sub>1</sub>-C<sub>4</sub> polyfluoroalkyl; straight chained or branched C<sub>1</sub>-C<sub>4</sub>

alkoxy;  $-(CH_2)_qOH$ ;  $-OH$ ;  $=N-OR_4$ ;  $COR_4$ ;  $CO_2R_4$ ;  $CONHR_4$ ; phenyl; or benzyl;

5 wherein each  $R_4$  is independently H; straight chained or branched  $C_1-C_4$  alkyl,  $C_1-C_4$  monofluoroalkyl or  $C_1-C_4$  polyfluoroalkyl; or phenyl;

10 wherein each  $R_5$  is independently H; straight chained or branched  $C_1-C_4$  alkyl,  $C_1-C_4$  monofluoroalkyl, or  $C_1-C_4$  polyfluoroalkyl;

15 wherein  $R_6$  is H; straight chained or branched  $C_1-C_4$  alkyl;  $C_1-C_4$  monofluoroalkyl or  $C_1-C_4$  polyfluoroalkyl; straight chained or branched  $C_1-C_4$  alkoxy;  $-CH_2CH_2(CH_2)_qOH$ ;  $COR_4$ ;  $CO_2R_4$ ;  $CONHR_4$ ; phenyl; or benzyl;

20 wherein each  $R_7$  is independently H;  $-CN$ ; straight chained or branched  $C_1-C_4$  alkyl;  $C_1-C_4$  monofluoroalkyl or  $C_1-C_4$  polyfluoroalkyl; straight chained or branched  $C_1-C_4$  alkoxy;  $-OH$ ;  $-(CH_2)_qOH$ ;  $-COR_4$ ;  $CO_2R_4$ ;  $CONHR_4$ ; phenyl; or benzyl;

25 wherein  $m$  and  $n$  are each independently 0, 1, 2 or 3, provided that  $m+n$  is 2 or 3;

wherein each  $p$  is independently 0, 1 or 2; and


wherein each  $q$  is independently 0, 1, 2 or 3;

30 or a pharmaceutically acceptable salt thereof.

26. A method for treating pain in a subject, which comprises administering to the subject an amount of a compound effective to treat the subject's pain, wherein the compound has the structure:

5

10



wherein each of Z1, Z2 and Z3 is N or CR<sub>2</sub>, with the proviso that either one of Z1, Z2 or Z3 is N and the others of Z1, Z2 or Z3 are CR<sub>2</sub>, or both Z1 and Z3 are N and Z2 is CR<sub>2</sub>;

15

wherein R<sub>1</sub> is H; F; straight chained or branched C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> monofluoroalkyl or C<sub>1</sub>-C<sub>4</sub> polyfluoroalkyl; straight chained or branched C<sub>1</sub>-C<sub>4</sub> alkoxy, -OH; or - (CH<sub>2</sub>)<sub>q</sub>OH;

20

wherein each R<sub>2</sub> is independently H; F; Cl; Br; I; -NO<sub>2</sub>, -CN; straight chained or branched C<sub>1</sub>-C<sub>4</sub> alkyl; C<sub>1</sub>-C<sub>4</sub> monofluoroalkyl or C<sub>1</sub>-C<sub>4</sub> polyfluoroalkyl; straight chained or branched C<sub>1</sub>-C<sub>4</sub> alkoxy; -OH; - (CH<sub>2</sub>)<sub>q</sub>OH; -COR<sub>4</sub>; CO<sub>2</sub>R<sub>4</sub>; CONHR<sub>4</sub>; phenyl; or benzyl;

25

wherein each R<sub>3</sub> is independently H; straight chained or branched C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> monofluoroalkyl or C<sub>1</sub>-C<sub>4</sub> polyfluoroalkyl; or phenyl; and

30

wherein q is each independently 0, 1, 2 or 3;

or a pharmaceutically acceptable salt thereof.

35